REFORM is indicated to treat type-2 diabetes.
Mode of Action
REFORM decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting plasma insulin levels and day-long plasma insulin response may actually decrease. It is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose.
The appearance of REFORM in plasma from an Extended-Release Tablet is slower and more prolonged compared to immediate-release metformin. REFORM is negligibly bound to plasma proteins, in contrast to sulfonylureas, which are more than 90% protein bound. It is excreted unchanged in the urine and does not undergo hepatic metabolism or biliary excretion.
Dosage and Recommendation
Type II diabetes: 500 mg extended release once daily, can increase maximum up to 2000 mg extended release once daily
Packing and Presentation
REFORM 500 SR / REFORM 850 SR and REFORM 1000 SR are available as a blister strip of 10 tablets in a box of 10 x 10s